Bryan, Garnier & Co's News

Read all the news of the independent investment banking dedicated to Growth
Share on
Filters

Net net, not so bad for Zealand ...

BUY, Fair Value DKK160 vs. DKK168 (+7%)

Published last October Friday 30, 2015

Novo Nordisk: Is Novo's central scenario realistic?

NEUTRAL, Fair Value DKK375 vs. DKK390 (+3%)

Published last October Friday 30, 2015

Sanofi: Diabetes guidance is updated and now what are we left with?

BUY, Fair Value EUR96 vs. EUR103 (+6%)

Published last October Friday 30, 2015

Altran Technologies: Q3 15 conference call feedback: working for turnaround in Germany

BUY, Fair Value EUR13 (+16%)

Published last October Friday 30, 2015

Bayer: Very solid earnings growth in Q3

NEUTRAL, Fair Value EUR124 (+5%)

Published last October Thursday 29, 2015
Bryan, Garnier & Co advised My Media Group on its Capital reorganization around its Management Team and Euromezzanine

Bryan, Garnier & Co advised My Media Group on its Capital reorganization around its Management Team and Euromezzanine

Published last October Thursday 29, 2015

ASK: Q3 up 19%, in line with expectations. The group confirms a better momentum in H2.

CORPORATE, Fair Value EUR2.4 (+75%)

Published last October Wednesday 28, 2015

DIA: The proponents of the margin restatement will have plenty to say ahead of Q4

NEUTRAL vs. BUY, Fair Value EUR7,5 vs. EUR8,5 (+21%)

Published last October Wednesday 28, 2015

Heineken: Q3 F15 trading update

BUY, Fair Value EUR85 vs. EUR75 (+6%)

Published last October Wednesday 28, 2015

Novartis: Fundamentals still there, momentum more questionable

BUY, Fair Value CHF107 vs. CHF110 (+20%)

Published last October Wednesday 28, 2015

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities